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Abstract: Diabetes mellitus is growing in pandemic proportions and is associated with significant
morbidity, mortality, and health care expenditure. Type 2 diabetes mellitus (T2DM) is the most common,
accounting for about 90–95% of diagnosed diabetes in United States adults. Individuals with T2DM have
a 2- to 3-fold increased risk of cardiovascular (CV) events compared with their non-diabetic counterparts,
and CV mortality is responsible for around 80% of the mortality in T2DM. Emerging evidence suggest that
in T2DM patients, hyperglycemia plays a little role in the progression of CV disease, and metabolic risk
factors like insulin resistance, hypertension, obesity, and dyslipidemia are the major culprits in the initiation
and progression of CV disease. This calls for development of drugs which control hyperglycemia as well
as the various metabolic risk factors in T2DM patients to improve CV outcomes. Recent clinical trials of
glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter-2 (SGLT-2)
inhibitors showed encouraging CV outcomes in T2DM patients, which are attributed to the diverse extrapancreatic effects of these medications. This review article will discuss the CV benefits of the newer incretin
based therapies and SGLT-2 inhibitors as observed in their CV safety trials. As T2DM or insulin resistance
syndrome, CV disease, and HF and frequently coexistent, it would be interesting to design studies evaluating
the combinations of GLP-1 RAs, SGLT-2 inhibitors, and pioglitazone in T2DM patient at an elevated CV
risk, and in non-diabetic patients with insulin resistance to study the possible CV protective role of these
combinations.
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Introduction
Diabetes mellitus is growing in pandemic proportions
and is associated with significant morbidity, mortality, and
health care expenditures. It affects more than 29 million
people in the United States (9.3% population), a trend if
continues can result in every third adult having diabetes
mellitus by 2050 (1). It affects around 415 million people
worldwide, a number that is projected to increase to
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642 million worldwide (12% population) by 2040, affecting
one in every 10 adults (2). In the Unites States diabetes
mellitus is the seventh leading cause of death, a number
that is underreported (1). Per the International Diabetes
Federation, 1 person dies from diabetes mellitus every
6 seconds around the world (2). The total cost of diabetes
mellitus is estimated to be more than $245 billion in the
United States and around $673 billion worldwide (1,2).
Type 2 diabetes mellitus (T2DM) is the most common,
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accounting for about 90–95% of diagnosed diabetes in
United States adults (1).
Individuals with T2DM have a 2- to 3-fold increased
risk of cardiovascular (CV) events compared with their
non-diabetic counterparts, and CV mortality is responsible
for around 80% of the mortality in T2DM (3,4). A metaanalysis showed that the relative risk (RR) for coronary
heart disease or stroke has been estimated at 1.18% for
every 1% increase in glycated hemoglobin (HbA1C) (5).
Available evidence suggests that hyperglycemia is a weak
risk factor for CV events, and tight glycemic control had
very little effect on reducing macrovascular events and CVrelated death (6,7). Intensive glycemic control increased
mortality without reducing CV events (8). In addition to
hyperglycemia, individuals with T2DM can have other
features of insulin resistance-metabolic syndrome like
hypertension, lipid abnormalities, and obesity which are all
associated with increased CV disease and stroke risk even
in the absence of T2DM (9,10). Thus, the management of
T2DM patients should include control of CV risk factors in
addition to hyperglycemia to improve both macrovascular
and microvascular complications and resulting morbidity
and mortality. With the increasing prevalence of T2DM
and metabolic syndrome, and associated significant CV
disease and mortality, there is a need for novel diabetic
medications which have a role in improving metabolic risk
factors in addition to hyperglycemia.
Metformin and pioglitazone has been shown to have
a CV protective benefit via their effect on improving
lipid profile, weight, and blood pressure (BP), and insulin
sensitivity (11,12). Metformin decreases gluconeogenesis in
liver, increases insulin sensitivity, and improves the efficacy
of endogenous insulin (11). A meta-analysis suggesting that
rosiglitazone was associated with significantly increased risk
of myocardial infarction (MI) and CV-related death led to
an intense debate about the CV safety of the antidiabetic
drugs (13). This led to regulatory agencies requiring CV
safety trials as part of the approval process for newer
antidiabetic drugs (14,15). This review article will discuss
the CV benefits of the newer incretin based therapies and
sodium glucose cotransporter-2 (SGLT-2) inhibitors as
observed in their CV safety trials.
Incretin based therapies
Incretins are insulinotropic intestinal hormones secreted
into the blood by the enteroendocrine cells in response in
oral glucose intake (16). These hormones then stimulate
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the secretion of insulin from the pancreatic ß-cells, a
phenomenon called the incretin effect (16). Two incretins,
glucose-dependent insulinotropic peptide and glucagon-like
peptide 1 (GLP-1) were characterized and studied in human
beings. Both the incretin hormones are rapidly degraded by
dipeptidyl peptidase-4 (DPP-4) in the circulation (16). The
insulinotropic effect of glucose-dependent insulinotropic
peptide is deficient in patients with T2DM thereby limiting
it from being a therapeutic target (16). The incretin effect of
GLP-1 is better preserved in T2DM patients, thus making
it a potential therapeutic target in this population (16).
GLP-1 also inhibits gastric emptying, decreases appetite,
inhibits glucagon secretion from pancreatic α-cells via a
paracrine effect medicated by somatostatin release, and
slows the rate of endogenous glucose production, all of
which improve glycemic control in T2DM (16). Two
approaches were devised to augment the beneficial role on
incretins in T2DM. One approach is the use of exogenous
GLP-1 agonists resistant to degradation by DPP-4. The
other approach is the use of DPP-4 inhibitors to enhance
the half-life and effects of endogenous GLP-1.
GLP-1 receptor agonists (RAs)
Currently available RAs include albiglutide once weekly,
dulaglutide once weekly, exenatide twice daily, extended
release exenatide once weekly, liraglutide once daily, and
lixisenatide once daily. A comprehensive review of all
head-to-head data indicates that liraglutide followed by
exenatide appear to offer the best HbA1C (approximately
1–2%) and weight reduction (17). Retrospective analyses
of data suggested a possible reduced likelihood of having
a CV event over a 1- to 4-year period among patients
who were treated with exenatide twice daily compared
with other glucose-lowering agents (18). In 2 recent large
randomized controlled trials, the GLP-1 RAs liraglutide
and semaglutide showed remarkable CV benefit compared
to placebo when added to patients with T2DM and high
CV risk (19,20). The perceived CV benefit of GLP-1 RAs
can be attributed to the extra-pancreatic pleotropic effects
of GLP-1 on the CV system, and the favorable impact of
GLP-1 RAs on important non-glycemic CV risk factors like
BP, weight, and lipid profile.
GLP-1 receptors are present on rodent and human
cardiac myocytes, endothelial cells, and vascular smooth
muscle cells (16). Numerous in vitro studies have
demonstrated the protective effects of liraglutide and
exenatide on endothelial cells independent of GLP-
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No established CVD

T2DM patients

Established CVD

In addition to first line diabetic therapies and
lifestyle/risk factor modification

> Standard oral diabetic therapy
(metformin/pioglitazone);
> Aggressive risk factor modification
with BP control, lipid control
(statin), lifestyle interventions.
> Randomized trials to evaluate
benefit of GLP-1 agonists and
SGLT-2 inhibitors in this group.

Consider GLP-1 agonist or SGLT-2 inhibitor as add on therapy
in patients with CVD. Role of combination therapy based on risk
factors/CVD is to be evaluated.

↑ eNOS, ↓ TNF alpha,
↓ PAI-1 etc

GLP-1 agonists
Better improvements
in vascular risk
factors/outcomes and
atherosclerosis.

↓ arterial stiffness.

HEART and
VASCULATURE

improved endothelial
dysfunction and ↓
atherosclerosis and intimal
hyperplasia.

↓ BP, ↓weight, ↓urinary
albumin secretion.

SGLT-2 inhibitors

Improve BP, lipid profile.

nephroprotective

Better improvements in
HF outcomes.

↓ gastric emptying, appetite,
glucagon secretion, glucose
production.

KIDNEYS

↓ glucose reabsorption in
the renal proximal tubule.

Figure 1 Approach to patients with type 2 diabetes mellitus (T2DM). Role of glucagon like peptide-1 (GLP-1) agonists and sodium glucose
contransporter-2 (SGLT-2) inhibitors. CVD, cardiovascular disease; eNOS, endothelial nitric oxide synthase; TNF, tumor necrosis factor;
PAI-1, plasminogen activator inhibitor 1; BP, blood pressure; ↓, decrease; ↑, increase.

1 RA glycemic and weight reduction effects (21,22).
The favorable effects on endothelial cells is mediated
via activation of endothelial nitric oxide synthase, and
inhibition of tumor necrosis factor alpha, plasminogen
activator inhibitor-1, various growth factors, and adhesion
molecules. Through these GLP-1 receptor-dependent
mechanisms, GLP-1 RAs improve endothelial dysfunction
and attenuate atherosclerosis and intimal hyperplasia.
Exenatide and liraglutide lowered BP, reduced myocardial
infarct size, and improved systolic and diastolic cardiac
function in various animal models of ischemia-reperfusion
injury and congestive heart failure (HF) (16,21,22).
Infusion of exenatide during two consecutive days in men
with T2DM and HF led to signiﬁcantly increased cardiac
index and decreased pulmonary capillary wedge pressure
compared to placebo (23) (Figure 1).
The CV benefit of GLP-1 RAs in terms of risk factor
improvement compared with placebo and most standard
anti-diabetic agents was observed in human clinical studies.
Treatment with liraglutide or exenatide was associated
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with modest systolic BP reductions (21). In a meta-analysis
of 33 trials (12,469 patients) in which 41% patients were
treated with liraglutide and the rest with exenatide, GLP1 RA treatment achieved a greater systolic BP reduction
than comparator therapy [weighted mean difference of
2.22 mmHg, 95% confidence interval (CI): −2.97 to −1.47]
independent of baseline BP, weight loss, or improvement
in HbA1C (24). Improvements in lipid profile by reducing
triglycerides, apolipoproteins B-48, free fatty acids, lowdensity lipoprotein cholesterol (LDL-C), and total
cholesterol was observed with GLP-1 RA treatment (21).
In a meta-analysis of 35 trials, GLP-1 RAs were associated
with modest reductions in LDL-C, total cholesterol, and
triglycerides but no significant improvement in high density
lipoprotein cholesterol (HDL-C) (25). Clinical studies
of liraglutide and exenatide also demonstrated significant
weight loss, and improvements in CV risk biomarkers like
plasminogen activator inhibitor-1 and high-sensitivity
C-reactive protein (16,21).
The Evaluation of Lixisenatide in Acute Coronary
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Syndrome (ELIXA) trial randomized 606 T2DM patients
who had a MI or who had been hospitalized for unstable
angina within the previous 180 days to receive lixisenatide
or placebo in addition to locally determined standards
of care (26). Primary end-point was a composite of CV
death, MI, stroke, or hospitalization for unstable angina. At
25-month follow up, the primary end-point event occurred
in 13.4% patients in the lixisenatide group and in 13.2% in
the placebo group [hazard ratio (HR) 1.02; 95% CI: 0.89
to 1.17], which showed the noninferiority of lixisenatide to
placebo (P<0.001) but did not show superiority (P=0.81).
There were no significant between-group differences in the
rate of hospitalization for HF (HR in the lixisenatide group,
0.96; 95% CI: 0.75 to 1.23) or the rate of death (HR, 0.94;
95% CI: 0.78 to 1.13). The authors concluded that the
addition of lixisenatide to usual care did not significantly
alter the rate of major CV events or other serious adverse
events (26).
The Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results (LEADER)
trial is a double-blind, placebo controlled trial that
randomized 9340 T2DM patients at high CV risk to either
1.8 mg (or the maximum tolerated dose) of liraglutide or
matching placebo once daily as a subcutaneous injection in
addition to standard care (19). High CV risk was defined
as age ≥50 years with at least one CV coexisting condition
(coronary heart disease, cerebrovascular disease, peripheral
vascular disease, chronic kidney disease of stage 3 or
greater, or chronic HF of New York Heart Association
class II or III) or an age ≥60 years with at least one CV
risk factor (microalbuminuria or proteinuria, hypertension
and left ventricular hypertrophy, left ventricular systolic or
diastolic dysfunction, or an ankle-brachial index of less than
0.9). The primary composite outcome in the time-to-event
analysis was the first occurrence of death from CV causes,
nonfatal MI, or nonfatal stroke. After a median follow up
of 3.8 years, significantly fewer patients in the liraglutide
group than in the placebo group experienced the primary
outcome (13.0% vs. 14.9%; HR 0.87; 95% CI: 0.78 to
0.97; P<0.001 for noninferiority; P=0.01 for superiority),
CV-related death (4.7% vs. 6.0%; HR 0.78; 95% CI: 0.66
to 0.93; P=0.007), or all-cause death (8.2% vs. 9.6%; HR
0.85; 95% CI: 0.74 to 0.97; P=0.02). In subgroup analysis,
the CV benefit of liraglutide was more apparent in patients
with established CV disease compared to placebo (14% vs.
16.7%; HR 0.83; 95% CI: 0.74 to 0.93; P=0.04).
The liraglutide group had non-significantly lower
frequencies of nonfatal MI, nonfatal stroke, HF
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hospitalization rate, and acute pancreatitis. At 36 months,
the liraglutide group had improved CV risk factor profile
in terms of higher weight loss (mean 2.3 kg; 95% CI: 2.5 to
2.0), lower systolic BP (1.2 mmHg; 95% CI: 1.9 to 0.5), and
a lower rate of nephropathy events (1.5 vs. 1.9 events per
100 patient-years of observation; HR 0.78; 95% CI: 0.67
to 0.92; P=0.003). The heart rate was 3.0 beats per minute
(95% CI: 2.5 to 3.4) higher in the liraglutide group (19).
The composite outcome of renal or retinal microvascular
events was lower in the liraglutide group than in the
placebo group (HR, 0.84; 95% CI: 0.73 to 0.97; P=0.02), a
difference that was driven by a lower rate of nephropathy
events in the liraglutide group (1.5 vs. 1.9 events per 100
patient-years of observation; HR, 0.78; 95% CI: 0.67
to 0.92; P=0.003). Retinopathy events were numerically
higher in the liraglutide group (0.6 vs. 0.5 events per 100
patient-years; HR, 1.15; 95% CI: 0.87 to 1.52; P=0.33) (19).
Hypoglycemic events and gastrointestinal side effects
(nausea, vomiting, diarrhea, abdominal discomfort,
cholelithiasis, and acute cholecystitis) were significantly
more frequent in the liraglutide group (19).
Semaglutide, a GLP-1 analogue with an extended halflife of approximately 1 week is currently in development
but not yet approved for the T2DM. The Trial to Evaluate
Cardiovascular and Other Long-term Outcomes with
Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6)
randomized 3,297 T2DM patients with either CV disease
(89.3%) or chronic kidney disease (10.7%) to once-weekly
subcutaneous semaglutide (0.5 or 1.0 mg) or placebo for
104 weeks in addition to standard-care regimen (20). The
primary composite outcome was the first occurrence of
CV death, nonfatal MI, or nonfatal stroke. After a median
follow up of 2.1 years, the primary outcome (6.6% in
semaglutide group vs. 8.9% in placebo group; HR, 0.74;
95% CI: 0.58 to 0.95; P<0.001 for noninferiority) occurred
in significantly fewer semaglutide patients than placebo
patients. There were significantly fewer nonfatal stroke
events (1.6% vs. 2.7%; HR, 0.61; 95% CI: 0.38 to 0.99;
P=0.04) and numerically fewer nonfatal MI events (2.9%
vs. 3.9%; HR 0.74; 95% CI: 0.51 to 1.08; P=0.12) in the
semaglutide group. Rates of CV-related death were similar
in the two groups. The mean HbA1C in the semaglutide
group, as compared with the placebo group, was 0.7
percentage points lower in the group receiving 0.5 mg
and 1.0 percentage point lower in the group receiving
1.0 mg (estimated treatment difference) (P<0.001 for both
comparisons). At 104 weeks, the semaglutide group had
improved CV risk factor profile in terms of higher mean
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weight loss (2.9 kg lower in the group receiving 0.5 mg
and 4.3 kg lower in the group receiving 1.0 mg; P<0.001
for both comparisons), lower mean systolic BP (1.3 mmHg
lower in the group receiving 0.5 mg, P=0.10; and 2.6 mmHg
lower in the group receiving 1.0 mg, P<0.001).
The semaglutide group had a lower rate of nephropathy
events (3.8% vs. 6.1%; HR 0.64; 95% CI: 0.46 to 0.88;
P=0.005). The mean heart rate was 2.0 bpm higher in the
group receiving 0.5 mg semaglutide and 2.5 bpm higher
in the group receiving 1.0 mg semaglutide (P<0.001 for
both comparisons) compared to placebo (20). Diabetic
retinopathy complications occurred in more semaglutide
treated patients (3% vs 1.8%; HR 1.76; 95% CI: 1.11 to
2.78; P=0.02), and were seen very early in the trial (20).
Although the overall number of retinopathy events was
low, there was an unexpected higher rate of retinopathy
complications (vitreous hemorrhage, blindness, or
the need for treatment with an intravitreal agent or
photocoagulation) in the semaglutide group. It must be
reminded that SUSTAIN-6 is a preapproval trial with a
relatively short duration (2.1 years) designed to test the
non-inferiority of semaglutide compared to placebo in
influencing CV events, but not to investigate the superiority
of semaglutide in reducing CV events. Results from this
trial are encouraging and hypothesis generating for future
research.
DPP-4 inhibitors
DPP-4 inhibitors are oral diabetic medications that prevent
the peripheral inactivation of incretins by DPP-4, resulting
in increased half-life, and extended insulinotropic and
other actions of GLP-1 in T2DM patients (27). Currently
approved DPP-4 inhibitors are sitagliptin, saxagliptin,
linagliptin, alogliptin, and vildagliptin. DPP-4 has many
substrates and thus inhibition of DPP-4 may have diverse
effects in addition to prolongation of incretin effect. DPP-4
can also degrade inflammatory chemokines, neuropeptides,
and vasodilatory/fibrinolytic peptides like substance P and
bradykinin (27). Although available data from early animal
and human studies showed a favorable effect of DPP4 inhibition on atherosclerosis, the effects on endothelial
function, vasodilatation, cardiac remodeling, and cardiac
function are inconsistent (27,28). DPP-4 inhibition was
associated with improved glycemic control, improved total
cholesterol and triglyceride levels, and weight neutrality
(27,29). The effects of DPP-4 inhibition on CV disease risk
factors, cardiac function, and vascular repair likely represent
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contributions from and a balance of both GLP-1-dependent
actions of DPP-4 inhibitors as well as mechanisms
independent of GLP-1 (27). Recent large clinical trials have
confirmed the safety and neutral effect of DPP-4 inhibitors
on CV outcomes.
The Saxagliptin Assessment of Vascular Outcomes
recorded in patients with diabetes mellitus-Thrombolysis
in Myocardial Infarction 53 (SAVOR-TIMI 53) study
randomized 16,492 patients with T2DM with established
CV disease or multiple risk factors for vascular disease,
to receive either daily saxagliptin or placebo in addition
to standard diabetic and CV disease therapy (30). At
median follow up of 2.1 years, saxagliptin did not increase
or decrease the risk of the primary composite end-point
of CV death, non-fatal MI or non-fatal ischemic stroke,
compared with placebo (HR, 1.00; 95% CI: 0.89 to 1.12;
P<0.001 for non-inferiority and P=0.99 for superiority).
The occurrence of the major secondary end-point of a
composite of CV death, MI, stroke, hospitalization for
unstable angina, coronary revascularization, or HF was
similar between the two groups (12.8% in saxagliptin group
vs. 12.4% in placebo group; HR, 1.02; 95% CI: 0.94 to 1.11;
P=0.66). More patients in the saxagliptin group than in the
placebo group were hospitalized for HF (3.5% vs. 2.8%;
HR, 1.27; 95% CI: 1.07 to 1.51; P=0.007) (30). A metaanalysis of randomized trials of DPP-4 inhibitors showed
that saxagliptin was significantly associated with a 21%
increased risk of HF (RR, 1.215; 95% CI: 1.028 to 1.437;
P=0.022) (31). The EXAmination of CV outcoMes with
alogliptIN versus standard of carE (EXAMINE) trial
randomized 5,380 T2DM patients with either an acute
MI or unstable angina requiring hospitalization within the
previous 15 to 90 days to receive alogliptin or placebo in
addition to existing antihyperglycemic and CV drug therapy
for a median follow up of 40 months (32). At 18-month
follow up, alogliptin did not increase or decrease the risk
of the primary composite end-point of CV death, nonfatal MI or non-fatal stroke, compared with placebo (11.3%
vs. 11.8%; HR, 0.96; upper boundary of the one-sided
repeated CI, 1.16; P<0.001 for non-inferiority; P = 0.32
for superiority). The analysis of the principal secondary
end-point of death from CV causes, nonfatal MI, nonfatal
stroke, or urgent revascularization due to unstable angina
showed no significant difference between the alogliptin
group and the placebo group (12.7% vs. 13.4%; HR, 0.95;
upper boundary of the one-sided repeated CI, 1.14) (32). In
a post hoc analysis, alogliptin did not significantly increase
the rates of HF hospitalization compared to placebo
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although a numerical increase was noted (3.9% vs. 3.3%;
HR, 1.19; 95% CI: 0.90 to 1.58) (33). Alogliptin had no
effect on composite events of CV and hospital admission
for HF in a post hoc analysis (HR 1·00; 95% CI: 0.82 to
1.21) and results did not differ by baseline b-type natriuretic
peptide concentration (34). An increase in hospitalization
for HF with alogliptin was noted in patients without a prior
history of HF (2.2% with alogliptin vs. 1.3% with placebo;
HR, 1.76; P=0.026) (34). Rates of CV death were similar
between alogliptin and placebo (4.1% vs. 4.9%, HR 0.85;
95% CI: 0.66 to 1.10) (35).
The Trial Evaluating Cardiovascular Outcomes with
Sitagliptin (TECOS) evaluated the long-term CV safety
of the DPP-4 sitagliptin in T2DM patient with CV
disease (36). TECOS randomized 14,671 T2DM patients
with established CV disease (history of major coronary
artery disease, ischemic cerebrovascular disease, or
atherosclerotic peripheral arterial disease) to either daily
oral sitagliptin or matching placebo in addition to existing
therapy (36). At median follow up of 3 years, sitagliptin
was noninferior to placebo for the primary composite
end-point of CV death, nonfatal MI, nonfatal stroke, or
hospitalization for unstable angina (11.4% vs. 11.6%; HR,
0.98; 95% CI: 0.88 to 1.09; P<0.001; HR in the intentionto-treat analysis, 0.98; 95% CI: 0.89 to 1.08; P=0.65 for
superiority). Similarly, sitagliptin was noninferior to placebo
for the secondary composite end-point of first confirmed
event of CV death, nonfatal MI, or nonfatal stroke (HR
in the per-protocol analysis, 0.99; 95% CI: 0.89 to 1.11;
P<0.001 for noninferiority; HR in the intention-to-treat
analysis, 0.99; 95% CI: 0.89 to 1.10; P=0.84 for superiority).
Sitagliptin did not increase the rates of HF hospitalization
(1.07 per 100 person-years vs. 1.09 per 100 person-years;
HR, 1.00; 95% CI: 0.83 to 1.20; P=0.98) (36). The TECOS
confirmed that adding sitagliptin to usual care did not
appear to increase the risk of major adverse CV events,
especially hospitalization for HF, or other adverse events.
In a pooled analysis of randomized trials in T2DM
patients comparing linagliptin to either placebo or an active
comparator medication, linagliptin was not associated with
an increased CV risk (37). The 27% increased risk of HF
hospitalization with the DPP-4 inhibitor saxagliptin as
observed in the SAVOR-TIMI 53 trial was not replicated
in the EXAMINE or the TECOS trials with alogliptin and
sitagliptin, respectively (38). The Canadian Network for
Observational Drug Effect Studies (CNODES) investigators
examined existing data from multiple cohorts of patients
(total of 1,499,650 patients, with 29,741 hospitalized for
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HF) to determine whether the use of incretin-based drugs,
as compared with oral antidiabetic-drug combinations,
in routine clinical practice is associated with an increased
risk of HF (38). In this retrospective observational
analysis, incretin-based therapy did not increase the rate of
hospitalization for HF among patients with a history of HF
(HR, 0.86; 95% CI: 0.62 to 1.19) or among those without
a history of HF (HR, 0.82; 95% CI: 0.67 to 1.00). These
results were similar for both DPP-4 inhibitors and GLP-1
RAs. The investigators concluded that incretin-based drugs
were not associated with an increased risk of hospitalization
for HF, as compared with commonly used combinations of
oral antidiabetic drugs (38).
In a meta-analysis of 54 randomized controlled trials of
DPP-4 inhibitors in 74,737 participants with a minimum
follow-up of 12 weeks, DPP-4 inhibitors were not associated
with an increased risk of HF compared to comparators (RR
1.106; 95% CI: 0.995 to 1.228; P=0.062) (31). The authors
noted a differential effect of each DPP-4 inhibitor on the
risk of HF. Use of saxagliptin significantly increased the
risk of HF by 21% especially among patients with high CV
risk (RR 1.215; 95% CI: 1.028 to 1.437; P=0.022), while
others were not associated with an increased HF risk (31).
Age ≥65 years, diabetes duration of ≥10 years and BMI
2
≥30 kg/m were associated with an increased risk of HF
among patients using saxagliptin (31). Based on available
data, the risk of HF with DPP-4 inhibitors is of definitive
concern and appears to be drug-specific. After reviewing
the data from SAVOR-TIMI 53 and EXAMINE trials, the
FDA found an increased risk of HF with saxagliptin and
alogliptin particularly in patients with underlying heart or
kidney disease and announced safety warnings to be added
to the labels of these two DPP-4 inhibitors (39).
SGLT2 inhibitors
SGLT-2 inhibitors are a novel class of medications that
improve glycemic control via reduced glucose reabsorption
in the renal proximal tubule resulting in glycosuria (40).
SGLT-2 is present in segment 1 of the proximal tubule
and normally accounts for around 90% of the glucose
reuptake (40). As SGLT-2 expression is highly specific
for the kidneys, SGLT-2 inhibitors should not affect
glucose transport in other tissues (41). SGLT-2 inhibitors
act independent of insulin secretion, severity of insulin
resistance, and pancreatic ß-cell failure (40). The above
unique mechanisms are responsible for the very low
potential of SGLT-2 inhibitors to cause hypoglycemia and

jtd.amegroups.com

J Thorac Dis 2017;9(7):2124-2134

2130

suggest that they may be effective across the spectrum of
T2DM disease progression. As they act within the tubule,
reduced glomerular filtration rate in chronic kidney disease
can reduce the efficacy and safety of SGLT-2 inhibitors
(40,41). Canagliflozin, dapagliflozin, and empagliflozin are
some of the approved SGLT-2 inhibitors.
SGLT-2 inhibitors improve both glycemic and nonglycemic risk factors in T2DM patients. They induce urinary
glucose losses around 40–80 g/day, resulting in decent
glycemic control (HbA1c reduction around 0.7%) (42).
This corresponds to around 200–300 kilocalories daily
which can result in a 2–3 kg body weight loss over 24–52
weeks (40). Most weight loss associated with SGLT2 inhibition was due to reduction in visceral fat which is
associated with increased risk of T2DM, CV complications
and overall mortality (40). SGLT-2 inhibitors showed a
consistent BP lowering effect, more systolic than diastolic,
without a compensatory increase in pulse rate, in multiple
clinical studies (43,44). The mechanism of BP reduction is
not entirely clear. Possible mechanisms include the osmotic
diuretic effect, weight reduction, and a possible direct
vascular effect via reducing arterial stiffness (40,44). In a
meta-analysis of 27 randomized controlled trials (n=12,960
participants), SGLT-2 inhibitors significantly reduced both
systolic BP (weighted mean difference of 4.0 mmHg) and
diastolic BP (weighted mean difference of 1.6 mmHg)
from baseline (43). SGLT-2 inhibitors were associated
with a small increase in both HDL-C and LDL-C levels
with concomitant reductions in triglyceride levels, the
effect of which on CV events is not very clear at this time
(40,45). SGLT-2 inhibition is also associated with reduced
glomerular hyperfiltration and urinary albumin excretion
which might suggest the nephroprotective effect of this
class of drugs (40 (Figure 1).
Several analyses of pooled data suggest that SGLT2 inhibitors do not appear to increase CV risk (40). The
best available data on the effects of SGLT-2 inhibition on
CV outcomes comes from the BI 10773 (Empagliflozin)
Cardiovascular Outcome Event Trial in Type 2 Diabetes
Mellitus Patients (EMPA-REG OUTCOME) study (46).
The EMPA-REG OUTCOME trial randomized 7020
T2DM patient with established CV disease to receive
either 10 or 25 mg of empagliflozin or placebo once daily
in addition to standard anti-hyperglycemic and CV disease
therapies (46). The primary outcome was a composite of
death from CV causes, nonfatal MI (excluding silent MI),
or nonfatal stroke. After a median 3.1 years, significantly
fewer patients in the empagliflozin group than in the
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placebo group experienced the primary outcome (10.5%
vs. 12.1%; HR in the empagliflozin group, 0.86; 95.02%
CI: 0.74 to 0.99; P=0.04 for superiority), which was largely
driven by the significantly lower CV-related death (3.7%
vs. 5.9%; 38% RR reduction; HR, 0.62; 95% CI: 0.49 to
0.77; P<0.001). There were no significant between-group
differences in the occurrence of MI or stroke (P=0.22). The
empagliflozin group had lower rates of hospitalization for
HF (2.7% vs. 4.1% in placebo group; 35% RR reduction),
and death from any cause (5.7% vs. 8.3% in placebo
group; 32% RR reduction; HR, 0.68; 95% CI: 0.57 to
0.82, P<0.001). The key secondary outcome which was a
composite of the primary outcome plus hospitalization for
unstable angina occurred in fewer empagliflozin treated
patients (12.8% vs. 14.3 % in the placebo group; HR,
0.89; 95% CI: 0.78 to 1.01; P<0.001 for noninferiority
and P=0.08 for superiority). Empagliflozin, as compared
with placebo, was associated with small reductions in
weight, waist circumference, uric acid level, and systolic
and diastolic BP with no increase in heart rate and small
increases in both LDL-C and HDL-C (46).
Studies examining renal outcomes with SGLT-2
inhibitors were also reported. In a study of 1450 T2DM
patients on metformin randomly assigned to either
canagliflozin or glimepiride, canagliflozin treated patients
had significantly less decline in estimated glomerular
filtration rate and greater reduction in urinary albuminto-creatinine ratio compared to glimepiride (47). The
authors concluded that canagliflozin, compared with
glimepiride, slowed the progression of renal disease over
2 years in patients with T2DM, and canagliflozin may
confer renoprotective effects independently of its glycemic
effects (47). This study was not designed nor powered
to compare the renoprotective effects of canagliflozin
versus glimepiride, so the results should be interpreted
as hypothesis-generating (47). Results of a prespecified
secondary end-point of the EMPA-REG OUTCOME trial
to evaluate the effects of empagliflozin on microvascular
outcomes were later published (48). Among patients with
glomerular filtration rates of ≥30 mL/minute/1.73 m 2,
incident or worsening nephropathy occurred in 12.7%
patients in the empagliflozin group and in 18.8% patients
in the placebo group (HR in the empagliflozin group, 0.61;
95% CI: 0.53 to 0.70; P<0.001), doubling of the serum
creatinine level occurred in 1.5% in the empagliflozin
group and in 2.6% in the placebo group (significant RR
reduction of 44%), renal-replacement therapy was initiated
in 0.3% in the empagliflozin group and in 0.6% in the
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placebo group (55% lower RR). Empagliflozin did not
prevent development of microalbuminuria (48). Studies
evaluating the CV benefit of canagliflozin [Canagliflozin
Cardiovascular Assessment Study (CANVAS)], dapagliflozin
[The Multicenter Trial to Evaluate the Effect of
Dapagliflozin on the Incidence of Cardiovascular Events
(DECLARE-TIMI58)], and ertugliflozin in T2DM patients
are currently undergoing (49-51).
Update on pioglitazone
Pioglitazone, a thiazolidinedione, acts by regulating
peroxisome proliferator-activated receptor-gamma mediated
gene expression resulting in increased insulin sensitivity and
glucose utilization, and decreased glucose production (12).
Pioglitazone has been shown to have a CV protective
benefit in diabetic patients via its effect on improving lipid
profile, weight, BP, and insulin sensitivity (12). The CV
effects of pioglitazone in non-diabetic patients with insulin
resistance has been recently investigated. , In the recent,
double-blind, controlled, Insulin Resistance Intervention
after Stroke (IRIS) study which randomized 3,876 nondiabetic patients with insulin resistance and a recent
ischemic stroke or transient ischemic attack to receive
either pioglitazone or placebo, pioglitazone reduced the
primary outcome of fatal or nonfatal stroke or MI (9% vs.
11.8% in the placebo group; HR in the pioglitazone group,
0.76; 95% CI: 0.62 to 0.93; P=0.007), without reducing allcause mortality at 4.8-year follow-up (52). Pioglitazone
also reduced incident diabetes mellitus (3.8% vs. 7.7%
in the placebo group; HR, 0.48; 95% CI: 0.33 to 0.69;
P<0.001) (52). These findings further support the fact that
improving metabolic control irrespective of the presence on
diabetes mellitus has an important role to play in improving
atherosclerotic risk factors and resultant CV disease in high
risk patients.
Role of incretin based therapies and SGLT-2
inhibition in the future of T2DM and CV disease
Recent years have been exciting for both cardiologists and
endocrinologists with the introduction of newer therapies
for T2DM with observed CV benefits in large randomized
trials. The primary outcome in these trials was a CV
composite of CV-related death, non-fatal MI, or nonfatal
stroke. In the LEADER trial, the GLP-1 RA liraglutide
significantly reduced the primary outcome, largely driven
by improvements in CV-related death and all-cause
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mortality (19). In the SUSTAIN-6 trial, semaglutide
significantly improved the primary outcome, an effect
that was largely driven by reduction of non-fatal stroke
events (20). In both the trials, there were numerically
fewer non-fatal MI events (19,20). Results from these
trials suggest that the CV benefit of GLP-1 RAs in T2DM
patients was driven by improvements in vascular risk factors
and atherosclerosis rather than improving HF. GLP-1 RAs
have extra-pancreatic actions on the CV system which are
probably responsible for the improvements noted in CV
risk factors like weight, BP, and lipid parameters. Although
the DPP-4 inhibitors extend the actions of endogenous
incretins, they appear to have diverse actions on other
inflammatory and metabolic pathways which could have
negated the CV protective role of prolonging GLP-1
activity. However, DPP-4 inhibitors were proven to be safe
from a CV standpoint based on the available recent data
despite concerns regarding increased HF risk prompting
the issue of FDA warnings (30,32,33,36-38).
In the EMPA-REG OUTCOME trial, empagliflozin,
with its renal-specific actions, dramatically reduced the
risk of CV deaths, HF hospitalizations, and all-cause
mortality with RR reductions of 30–40% in these outcomes,
prompting cardiologists to prescribe this medication to
T2DM patients at risk for HF (46). Significant improvement
in primary outcome from this trial was largely driven by
reduced mortality and HF hospitalization rate rather than
prevention of vascular/atherosclerotic events. The reduced
HF hospitalizations could be from the diuretic action and
BP lowering effect of empagliflozin (53). This mechanism of
action, along with proven benefit in a large randomized trial,
can make empagliflozin an important component of T2DM
therapy in patients with HF with reduced ejection fraction.
Empagliflozin caused slight improvements in other CV risk
factors like weight, BP, and lipid profiles (46). Interestingly,
in this trial, improvement in the primary outcome and HF
hospitalizations was apparent very early in the course of the
trial at around 3 months from randomization and persisted
throughout the duration of the study (46). Improvements
in mortality occurred early and improved across the 3-year
study period (46). Also important are the nephroprotective
actions of SGLT-2 inhibitors as observed with canagliflozin
and empagliflozin. Nephroprotection is important in
patients with CV disease and HF as worsening kidney
function can mutually worsen HF. Further larger studies
which are currently undergoing will provide clarity on the
nephroprotective actions of SGLT-2 inhibitors (40). Given
the possibility of differential improvements in CV disease
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from GLP-1 agonists and SGLT-2 inhibitors, future research
should include trials to evaluate the beneficial effects of the
combination of these drugs to improve atherosclerotic and
HF outcomes (Figure 1).
Conclusions
T2DM is growing in pandemic proportions and is likely to
affect a large proportion of adult population worldwide in the
coming years. Being associated with significant morbidity,
mortality, and health care expenditures, it is imperative to
control the responsible risk factors. Metabolic and CV risks
pose a major threat in the T2DM population accounting for
its major healthcare implications. Emerging evidence suggest
that in T2DM patients, hyperglycemia plays a little role in
the progression of CV disease, and metabolic risk factors like
insulin resistance, hypertension, obesity, and dyslipidemia
are the major culprits in the initiation and progression of
CV disease. Hence it is imperative to adopt a holistic risk
factor control approach when managing a T2DM patient.
Interestingly, newer anti-hyperglycemic medications like
the GLP-1 RAs and SGLT-2 inhibitors showed promise
in recent clinical trials in terms of providing CV benefit
irrespective of the glycemic control. However, these findings
were largely apparent in patients with established CV disease
as they were more represented in the randomized controlled
trials evaluating these drugs. Currently undergoing larger
trials will provide more information and clarity on the CV
protective role of these newer medications. Studies evaluating
the CV protective role of the newer T2DM medications
in patients without established CV disease are necessary to
establish the role of these drugs in the treatment paradigm
of T2DM. As T2DM or insulin resistance syndrome, CV
disease, and HF are frequently coexistent, it would be
interesting to design studies evaluating the combinations of
GLP-1 RAs, SGLT-2 inhibitors, and pioglitazone in T2DM
patient at an elevated CV risk, and in non-diabetic patients
with insulin resistance to study the possible CV protective
role of these combinations.
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